| Literature DB >> 35407014 |
Hui Yu1,2, Xiangzhou Yi1,2, Xia Gao1,2, Jun Ji1,2, Zhongyuan Liu1,2,3, Guanghua Xia1,2,3, Chuan Li1,2,3, Xueying Zhang1,2,3, Xuanri Shen1,2,3.
Abstract
We isolated and characterized tilapia-head chondroitin sulfate (TH-CS) and explored its biological activity and mechanisms of action as an oral supplement for nonalcoholic fatty liver disease (NAFLD) induced by a high-fat diet (HFD) in mice. The results showed that treatment with TH-CS for 8 weeks alleviated the development of NAFLD, as evidenced by the notable improvement in liver damage, blood lipid accumulation and insulin resistance (IR). Meanwhile, TH-CS treatment reduced the expression of proinflammatory cytokines and normalized oxidative stress. Additionally, the analysis of 16S rDNA sequencing revealed that TH-CS could restore gut microbiota balance and increase the relative abundance of short-chain fatty acid (SCFA)-producing bacteria. Furthermore, SCFAs produced by related bacteria can further improve lipid metabolism and IR by regulating lipid synthesis signals. In conclusion, TH-CS is an effective dietary supplement for the prevention of NAFLD, and may serve as a potential supplementary treatment for lipid-related metabolic syndrome.Entities:
Keywords: chondroitin sulfate; gut–liver axis; nonalcoholic fatty liver disease; tilapia head
Year: 2022 PMID: 35407014 PMCID: PMC8997817 DOI: 10.3390/foods11070922
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Primer sequences of Real-time PCR.
| Gene | Forward Primer | Reverse Primer |
|---|---|---|
| GPR41 | ACCACTATTTACCTCACCTCCCTCTTC | CGATGCCAGGAACCAACAGACTAC |
| GPR43 | TGCACCATCGTCATCATCGTTCAG | AGTTCTCGTAGCAGGTTATTTGGTTCTC |
| AMPK | TCCACAGAGATCGGGATCAGTTAGC | GAGTTAGGTCAACAGGAGAAGAGTCAAG |
| PPAR | AGCCCTTTACCACAGTTGATTTCTCC | GCAGGTTCTACTTTGATCGCACTTTG |
| SREBP-1c | CCTGCTTGGCTCTTCTCTTTGTCTAC | AGGTCAGCTTGTTTGCGATGTCTC |
| FAS | GTTTAAAGCTGAGGAGGCGGGTTC | GTTTTCAGGTTGGCATGGTTGACAG |
| GAPDH | AAGAAGGTGGTGAAGCAGGCATC | CGGCATCGAAGGTGGAAGAGTG |
Figure 1Chemical properties of TH-CS. (A) MW of TH-CS; (B) FT-IR analysis of TH-CS; (C) ion chromatograms of a mixture of 10 monosaccharide standards; (D) ion chromatograms of TH-CS. Peaks: (1) Fuc, (2) GalN, (3) Rha, (4) Ara, (5) GlcN, (6) Gal, (7) Glc, (8) Xyl, (9) Man and (10) GlcA; (E) 1H NMR spectra of TH-CS.
Figure 2TH-CS alleviated obesity, liver function and IR in NAFLD mice. (A) Body weight; (B) food intake; (C) Lee’s index; (D) the liver index; (E) the levels of AST in the serum; (F) the levels of ALT in the serum; (G). HOMA-IR. Values were expressed as mean ± SEM in each group. * p < 0.05 as compared to the model group; ** p < 0.01 as compared to the model group. (n = 6).
Figure 3TH-CS attenuated lipid accumulation in sera and livers of NAFLD mice. (A) Changes in liver morphology; (B) oil red O staining of the liver histology was photographed at 400× magnification; (C) H&E staining of the liver histology was photographed at 400× magnification; (D) serum TC; (E) serum TG; (F) FFA level in liver; (G) serum HDL-C; (H) serum LDL-C. Values were expressed as mean ± SEM in each group. * p < 0.05 as compared to the model group; ** p < 0.01 as compared to the model group. (n = 6).
Figure 4TH-CS regulates liver inflammation, hepatic oxidative stress and obesity factors in NAFLD mice. (A) Liver IL-6 level; (B) liver TNF-α level; (C) liver SOD level; (D) liver MDA level; (E) liver GSH level; (F) serum ADPN level; (G) serum LEP level. Values were expressed as mean ± SEM in each group. ** p < 0.01 as compared to the model group. (n = 6).
Figure 5TH-CS moderates intestinal microecology in NAFLD mice. (A) Chao1 index; (B) ACE index; (C) nonmetric multidimensional scaling (NMDS) analysis based on Bray–Curtis distance; (D) microbial community profiling in the phylum level for each group; (E) the relative abundance of certain bacteria in genus level. Values were expressed as mean ± SEM in each group. * p < 0.05 as compared to the model group; ** p < 0.01 as compared to the model group. (n = 5).
Figure 6TH-CS modulates the levels of SCFAs and metabolic gene expression in NAFLD mice. (A) The total levels of SCFAs; (B) the levels of specific SCFAs; (C) the mRNA expressions of GPR41, GPR43, AMPK, PPARγ, SREBP-1c and FAS. (D) Representative images of the Western blotting for AMPK, p-AMPK, PPARγ, SREBP-1c, FAS in the liver, with β-actin applied as a loading control. (E) The protein expressions of AMPK, phosphorylation of AMPK, SREBP-1c, PPARγ and FAS. Values were expressed as mean ± SEM in each group. * p < 0.05 as compared to the model group; ** p < 0.01 as compared to the model group. (n = 6).